REFERENCES
- Clozapine (Clozaril™) Datasheet. Rosedale, New Zealand: Novartis. http//www.medsafe.govt.nz
- Davis JM, Chen N, Click ID. Meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60: 553–564.
- Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th. London: Informa Healthcare, 2007.
- Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. Journal of Clinical Psychiatry 2008; 69: 759–68.
- Hibbard KR, Propst A, Frank DE, Wyse J. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. Psychosomatics 2009; 50: 416–419.
- Atkin K, Kendal F, Gould D, Freeman H, Lieberman J, O'Sullivan D. Neuropenia and agranulocystosis in patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry 1996; 169: 483–488.
- Sim K, Yong TW, Liew E, Choon CH. Clozapine-associated pseudomembranous colitis (letter). Journal of Clinical Psychopharmacology 2006; 26: 89.
- Pelizza L, Melegari M. Clozapine-induced microscopic colitis. Journal of Clinical Psychopharmacology 2007; 27: 571–574.
- McKean A, Vella-Brincat J, Begg E. Prescribing and monitoring of clozapine in Christchurch. Australasian Psychiatry 2008; 16: 263–267.